Results 131 to 140 of about 30,003 (287)

Adalimumab Monotherapy or Combination Therapy With Methotrexate in Paediatric Uveitis: Data From the AIDA Network Uveitis Registry

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background The study objective was to compare the effectiveness of adalimumab (ADA) in monotherapy and in combination with methotrexate (MTX) for paediatric noninfectious uveitis (NIU). Methods Registry‐based observational study. Children receiving ADA for active uveitis were divided into the ADA monotherapy group (group 1) and the ADA plus ...
Carla Gaggiano, Alejandra de‐la‐Torre, Silvana Guerriero, Stefania Costi, Gaafar Ragab, Maria Pia Paroli, Emanuela Del Giudice, Luciana Breda, Saverio La Bella, Marco Cattalini, Maria Cristina Maggio, Alex Fonollosa, Ester Carreño, Maria Tarsia, Rosanna Dammacco, Soad Hashad, Antonio Vitale, Lampros Fotis, Stefano Gentileschi, Francesca Minoia, Germán Mejía‐Salgado, Halah Etayari, Paola Saboya‐Galindo, María Andrea Bernal‐Valencia, Adele Civino, Maria Sole Chimenti, Valeria Caggiano, Maria Francesca Gicchino, Jurgen Sota, Angela Mauro, Giuseppe Lopalco, Kalpana Babu Murthy, Mohamed Tharwat Hegazy, Vishali Gupta, Francesco La Torre, Rana Hussein Amin, Bruno Frediani, Gian Marco Tosi, Luca Cantarini, Claudia Fabiani, on behalf of the AIDA Network   +40 more
wiley   +1 more source

Basic Facts about Biosimilars [PDF]

, 2007
Michał Nowicki
openalex   +1 more source

Biosimilars and Novel Insulins

American Journal of Therapeutics, 2020
Background: Insulin therapy is the mainstay of treatment for type 1 diabetes and may be necessary in type 2 diabetes. Current insulin analogues present a more physiological profile, are effective, and with less risk of hypoglycemia, but they are expensive.
openaire   +4 more sources

First‐line treatment of osteoporosis with osteoanabolic therapy: a new opportunity

Internal Medicine Journal, EarlyView.
Abstract Osteoporosis is a national health priority, and over six million Australians over the age of 50 years have poor bone health. Fragility fractures due to osteoporosis are associated with an increased morbidity and mortality risk and a high economic cost to the community. It is a chronic condition requiring long‐term management.
Jasna Aleksova, Peter Ebeling
wiley   +1 more source

Biosimilars and biopharmaceuticals: what the nephrologist needs to know--a position paper by the ERA-EDTA Council [PDF]

, 2009
Stanley Shaldon
openalex   +1 more source

Drug survival of IL‐23 and IL‐17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Psoriasis affects 2–3% of the population, with numerous biologic options complicating treatment selection. This real‐world study found IL‐23p19 inhibitors offer the longest‐lasting effectiveness and safety. Psoriatic arthritis reduced ustekinumab survival, and prior biologic use impacted persistence, especially for IL‐17 inhibitors.
Leila Motedayen Aval, Zenas Z. N. Yiu, Oras A. Alabas, Christopher E. M. Griffiths, Nick J. Reynolds, Philip J. Hampton, Catherine H. Smith, Richard B. Warren, BADBIR Study Group   +8 more
wiley   +1 more source

Patent and Regulatory Landscape of Biosimilars in the United States and Europe: Implications for Advancing the Domestic Biosimilar Industry with a Focus on Anti-TNF-α Biopharmaceuticals

Journal of Intellectual Property
Biopharmaceuticals exhibit excellent therapeutic efficacy; however, their high cost remains a significant limitation. The introduction of biosimilars is expected to enhance market competition and reduce biopharmaceutical prices.
Tae-Kwon Kim, Tai-Hyun Kang
doaj   +1 more source

Competitive Entry in the Market for Branded Generic Drugs

Journal of Economics &Management Strategy, EarlyView.
ABSTRACT I analyze the determinants of lead time (the time lag between the first‐mover's product release and the competitor's market entry) and its consequences for product prices, competition, and consumers. I investigate the case for the Indian branded generic pharmaceutical sector where substantial variation in lead time is observed.
Vasudha Wattal
wiley   +1 more source

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

Drug Design, Development and Therapy, 2017
Martin Schiestl,1 Markus Zabransky,2 Fritz Sörgel3,4 1Sandoz GmbH, Kundl, Austria; 2Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany; 3Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany; 4Institute of ...
Schiestl M, Zabransky M, Sörgel F
doaj  

The Role of Recombinant Human Growth Hormone Biosimilars in the Management of Growth Disorders [PDF]

, 2009
T E Romer
openalex   +1 more source